2023
Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN)
Stoller S, Capozza S, Alberti P, Lustberg M, Kleckner I. Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN). Supportive Care In Cancer 2023, 31: 293. PMID: 37086308, DOI: 10.1007/s00520-023-07734-2.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neurotoxicityPhysical therapy guidelinesPhysical therapistsPhysical therapyCIPN assessmentPeripheral neurotoxicityOncology teamTherapy guidelinesHome-based exercise prescriptionBurden of chemotherapyManual therapy interventionsClinical practice guidelinesPhysical therapy assessmentLimited effective treatmentsQuality of lifePhysical performance measuresSymptom management researchCIPN treatmentNeurologic symptomsMotor dysfunctionPatient functionExercise prescriptionAerobic trainingChemotherapy agentsPractice guidelines
2017
Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Monfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton M, Loprinzi C, Chaudhari A, Lustberg M. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Research And Treatment 2017, 164: 69-77. PMID: 28374323, PMCID: PMC5510549, DOI: 10.1007/s10549-017-4230-8.Peer-Reviewed Original ResearchConceptsBreast cancer patientsPatient-reported outcomesTaxane-based chemotherapyCancer patientsChemotherapy cyclesEarly-stage breast cancer patientsPatient-reported symptom severityDevelopment of CIPNSubsequent chemotherapy cyclesFirst chemotherapy cyclePatient-reported symptomsDose-limiting toxicityOutpatient oncology clinicsSelf-reported symptomsTaxane infusionTaxane therapyTaxane treatmentCIPN symptomsDose intensityPeripheral neuropathyOncology clinicPatient functionPhysical functionFunctional deficitsGait testing